Quest Diagnostics Inc. vs Johnson & Johnson
DGX vs JNJ — side-by-side comparison from reported financials. DGX leads 2, JNJ leads 8 of 10 comparable metrics.
Quest Diagnostics Inc.
DGX · Healthcare
$230.97+0.07%Mixed
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | DGX | JNJ |
|---|---|---|
| Price | $230.97 | $261.79 |
| Market cap | $25.5B | $631B |
| Revenue (TTM) | $11.6B | $97.9B |
| Revenue growth | +3.7% | +5.6% |
| Net margin | 9.2% | 21.5% |
| Free cash flow | $1.35B | $22.2B |
| Net cash (debt) | ($4.75B) | ($27.8B) |
| 1-year price return | +27.3% | +37.0% |
| P/E | 24.0 | 29.9 |
| P/E vs own history (cheap-side %) | 5% | 16% |
| Dividend yield | 1.42% | 2.00% |
| Return on equity | 14% | 26% |
| CV checks passed | 10 of 11 | 10 of 11 |
| Employees | 57,000 | 140,800 |
Full résumé-style profiles: DGX CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.